Arcus Biosciences
RCUS
210 hedge funds and large institutions have $2.57B invested in Arcus Biosciences in 2026 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 81 increasing their positions, 57 reducing their positions, and 33 closing their positions.
250% more call options, than puts
Call options by funds: $12.6M | Put options by funds: $3.61M
42% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 57
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
15% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 33
0% more funds holding
Funds holding: 209 → 210 (+1)
11% less capital invested
Capital invested by funds: $2.89B → $2.57B (-$321M)
17.48% less ownership
Funds ownership: 112.48% → 95% (-17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$26.5M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$25.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$19.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$18.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$8.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$68M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$35.4M |
| 3 |
Barclays
London,
United Kingdom
|
-$22.4M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$20.3M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$19.4M |
RCUS Hedge Fund Activity: Q1 2026 in Review
210 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2026, worth a combined $2.57B — down 11% from $2.89B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new RCUS positions and 33 closed out — a net gain of 5 holders — while 81 added to existing stakes and 57 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $26.5M. The largest seller was Point72 Asset Management, cutting an estimated $68M.
- 210 institutional investors held Arcus Biosciences (RCUS) as of Q1 2026, up from 209 in Q4 2025.
- Funds reported $2.57B of Arcus Biosciences stock for Q1 2026, down 11% quarter-over-quarter.
- 38 funds opened new Arcus Biosciences positions in Q1 2026 and 33 closed out, a net change of +5 holders.
- The largest Arcus Biosciences buyer in Q1 2026 was Citadel Advisors, an estimated $26.5M added.
- The largest Arcus Biosciences seller in Q1 2026 was Point72 Asset Management, an estimated $68M sold.
Based on aggregated 13F filings for Q1 2026.